These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14717955)

  • 21. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
    Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
    Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Manifestation of Fabry disease in a heterozygous female patient. New perspectives using enzyme replacement therapy].
    Jansen T; Brokalaki E; Hillen U; Hentschke M; Grabbe S
    Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1590-3. PubMed ID: 16823707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
    Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
    Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosing Fabry disease--delays and difficulties within discordant siblings.
    Brady M; Montgomery E; Brennan P; Mohindra R; Sayer JA
    QJM; 2015 Jul; 108(7):585-90. PubMed ID: 23378663
    [No Abstract]   [Full Text] [Related]  

  • 29. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.
    Jardim L; Vedolin L; Schwartz IV; Burin MG; Cecchin C; Kalakun L; Matte U; Aesse F; Pitta-Pinheiro C; Marconato J; Giugliani R
    J Inherit Metab Dis; 2004; 27(2):229-40. PubMed ID: 15159654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fabry disease: a little-known metabolic disorder with severe consequences].
    Jansen T; Grabbe S
    MMW Fortschr Med; 2006 Nov; 148(48):46-7. PubMed ID: 17615772
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients.
    Nishino T; Obata Y; Furusu A; Hirose M; Shinzato K; Hattori K; Nakamura K; Matsumoto T; Endo F; Kohno S
    Ren Fail; 2012; 34(5):566-70. PubMed ID: 22563919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].
    Zito A; De Pascalis A; Armeni A; Ria P; Barbarini L; Caggiula M; My F; Barbarini S; Trianni G; Napoli M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
    Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
    Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
    Linthorst GE; Hollak CE; Donker-Koopman WE; Strijland A; Aerts JM
    Kidney Int; 2004 Oct; 66(4):1589-95. PubMed ID: 15458455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal transplantation between siblings with unrecognized Fabry disease.
    Taneda S; Honda K; Nakajima I; Huchinoue S; Oda H
    Transplant Proc; 2013; 45(1):115-8. PubMed ID: 23375284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease.
    Lenders M; Boutin M; Auray-Blais C; Brand E
    Gastroenterology; 2020 Oct; 159(4):1602-1604. PubMed ID: 32534932
    [No Abstract]   [Full Text] [Related]  

  • 39. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease.
    Hoffmann B; Reinhardt D; Koletzko B
    Eur J Gastroenterol Hepatol; 2004 Oct; 16(10):1067-9. PubMed ID: 15371935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.